fbpx

   

November 2022 FDA Regulations HCT/Ps: Summary

INTRODUCTION, Page 1, Paragraph 3 In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should be in Agency guidances means that something is suggested or recommended, but not required.

II QUESTIONS AND ANSWERS A. 1. Paragraph 1 HCT/Ps that meet all of the criteria in 21 CFR 1271.10(a) are subject only to regulation undersection 361 of the Public Service Act (PHS Act) and the regulations in 21 CFR Part 1271. AnHCT/P that falls into this category is sometimes referred to as a "361 HCT/P" and no premarket authorization is required.

A. 2. Paragraph 1 To further assist HCT/P manufacturers, FDA issued the Guidance for Industry, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use", dated November 2017 and updated July 2020.

SARA ORACLE CEO and President

CONTACT FOR
Leading HCT/P Therapeutics
For IND and IRB Studies or
Contract Manufacturing.
FDA Regulation Changes.
Business Partnerships and M & A
Investment Placement.

Test tube Image

GO BEYOND with RICHSOURCE. Our name RichSource is based on the highest standards and quality to provide clinical researchers and regenerative medicine providers reliable facts on industry advances.
The RichSource trusted educational and research protocol plans and understanding of industry guidance and regulation.
Benefit from the business development leader - RichSource consulting services and HCT/P therapeutics information.

GO BEYOND poorly sourced biologics. Who is who? RichSource for years has private labeled, represented and distributed its own and several other top lab biologic therapeutics (MSCs and acellular nanoparticles). This experience gives RichSource consultants industry “inside knowledge” and continuing relationships with the top MD, CSO and COO heads. Contact RichSource for confidential negotiations for M&As, investing in biologic tissue banks, certified labs, R&D, pre-IPO and IPO raises, and other business expansion opportunities that have passed rigid review.
Be informed.

WHY USE RICHSOURCE BUSINESS CONSULTING SERVICES?

RICHSOURCE consulting developed from years of experience of being on the inside of regenerative nanomedicine. Now with the industry changes, RICHSOURCE is involved in joint venture expansion for tissue banks/ bio labs and large practices.

* Having represented multiple bio-ethical, natural HCT/P product lines of tissue banks.
* Access to upcoming new natural life science products.
* Best ozone generator, shockwave, laser devices and other application products.
* Knowledge of FDA HCT/P 351 and 361 regulations and standards for public safety and product quality. AATB and AABB guidelines.
* Knowing the Who's Who in the industry RICHSOURE has access to match the best parties for leading edge projects, clinical trials and off-shore clinic development.
* Developed treatment protocols reference material for a broad spectrum of biological functions and therapeutic potential.
* Creating practice pricing spreadsheets increasing margins.
* Targeted efficient marketing packages to increase patient participation.
* Demonstrating increased patient participation by presenting information about the benefits of Regenerative NanoMedicine and how to introduce medical tourism to your practice.

PRODUCTS AVAILABLE AT RICHSOURCE

UMBILICAL CORD BLOOD TRANSFUSIONS 25 ml BAGS and 8 M, 15 M and 30M 1 ml/cc Vials are available.

IND submitted Clinical Trial Research for SI Joint has now been FDA approved, October 2021, to begin testing with the top umbilical cord blood product made in FL. Please contact RichSource if you would like to order this product for your research.

Click on the brochure arrow for information on 25 ml UCB bags.

Announcement:
Cord Blood Clinical Trial Receives FDA Authorization

8M

15M

30M

 

WEBER MEDICAL

New Infrared Laser Products For Advanced Use

- Laser needle topical therapy
- Infrared, red, blue, green & yellow lasers
- UV laser accessory to treat covid-19
- FDA cleared

 

RICHSOURCE® unparalleled consulting gives you a comprehensive up to date insight into the regenerative therapy fields best products, options and resources tested, used or researched by RICHSOURCE®. M&A, partnerships and funding.

Patients

Please CONTACT US to be referred to one of our physicians for treatment off-shore.